NZ525119A - Propionic acid derivatives - Google Patents

Propionic acid derivatives

Info

Publication number
NZ525119A
NZ525119A NZ525119A NZ52511901A NZ525119A NZ 525119 A NZ525119 A NZ 525119A NZ 525119 A NZ525119 A NZ 525119A NZ 52511901 A NZ52511901 A NZ 52511901A NZ 525119 A NZ525119 A NZ 525119A
Authority
NZ
New Zealand
Prior art keywords
methyl
amino
phenyl
group
compounds
Prior art date
Application number
NZ525119A
Other languages
English (en)
Inventor
Klaus Urbahns
Michael Woltering
Susanne Nikolic
Josef Pernerstorfer
Berthold Hinzen
Elke Dittrich-Wengenroth
Hilmar Bischoff
Claudia Hirth-Dietrich
Klemens Lustig
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10124905A external-priority patent/DE10124905A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NZ525119A publication Critical patent/NZ525119A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ525119A 2000-10-05 2001-09-24 Propionic acid derivatives NZ525119A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10049208 2000-10-05
DE10124905A DE10124905A1 (de) 2000-10-05 2001-05-22 Propionsäurederivate
PCT/EP2001/011005 WO2002028821A2 (de) 2000-10-05 2001-09-24 Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften.

Publications (1)

Publication Number Publication Date
NZ525119A true NZ525119A (en) 2005-04-29

Family

ID=26007267

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ525119A NZ525119A (en) 2000-10-05 2001-09-24 Propionic acid derivatives

Country Status (22)

Country Link
EP (1) EP1328508A2 (de)
JP (1) JP2004510757A (de)
CN (1) CN1479716A (de)
AU (1) AU2001293838A1 (de)
BG (1) BG107684A (de)
BR (1) BR0114437A (de)
CA (1) CA2424540A1 (de)
CZ (1) CZ2003964A3 (de)
EE (1) EE200300140A (de)
HN (1) HN2001000223A (de)
HR (1) HRP20030346A2 (de)
HU (1) HUP0302306A3 (de)
IL (1) IL155125A0 (de)
MA (1) MA25917A1 (de)
MX (1) MXPA03002901A (de)
NO (1) NO20031517L (de)
NZ (1) NZ525119A (de)
PL (1) PL361162A1 (de)
RU (1) RU2003112968A (de)
SK (1) SK4132003A3 (de)
UY (1) UY26951A1 (de)
WO (1) WO2002028821A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10151390A1 (de) * 2001-10-18 2003-05-08 Bayer Ag Essigsäurederivate
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
BR0315596A (pt) * 2002-10-21 2005-09-06 Janssen Pharmaceutica Nv Tetralinas e indanos substituìdos
CN100354259C (zh) 2002-10-21 2007-12-12 詹森药业有限公司 取代的四氢化萘和茚满及其用途
MXPA05004296A (es) * 2002-10-21 2005-11-23 Johnson & Johnson Tratamiento del sindrome x con tetralinas e indanos sustituidos.
EP1583754A1 (de) 2003-01-06 2005-10-12 Eli Lilly And Company Thiophenderivate ppar modulatoren
JP4947406B2 (ja) 2003-08-29 2012-06-06 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその医薬用途
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
KR100699928B1 (ko) 2004-10-05 2007-03-26 재단법인서울대학교산학협력재단 퍼록시솜 증식자 활성화 수용체 알파 리간드를 제조하기위한 중간체의 제조방법
AU2005314938B2 (en) 2004-12-13 2011-06-09 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
TW201022221A (en) 2008-12-01 2010-06-16 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivatives containing thiazole ring and pharmaceutical use thereof
JP5436941B2 (ja) * 2009-06-03 2014-03-05 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
EP3230304B1 (de) * 2014-12-11 2020-01-01 Centrient Pharmaceuticals Netherlands B.V. Verfahren zur acylierung eines cyclischen peptids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
HUP0302306A2 (hu) 2003-10-28
IL155125A0 (en) 2003-10-31
WO2002028821A2 (de) 2002-04-11
BG107684A (bg) 2003-10-31
HRP20030346A2 (en) 2005-04-30
WO2002028821A3 (de) 2002-08-15
NO20031517D0 (no) 2003-04-03
AU2001293838A1 (en) 2002-04-15
MA25917A1 (fr) 2003-10-01
CZ2003964A3 (cs) 2003-08-13
UY26951A1 (es) 2002-06-20
HUP0302306A3 (en) 2005-02-28
SK4132003A3 (en) 2004-02-03
NO20031517L (no) 2003-05-28
CA2424540A1 (en) 2003-04-02
CN1479716A (zh) 2004-03-03
BR0114437A (pt) 2003-07-01
RU2003112968A (ru) 2004-09-20
MXPA03002901A (es) 2003-10-15
HN2001000223A (es) 2001-10-25
EE200300140A (et) 2003-08-15
JP2004510757A (ja) 2004-04-08
EP1328508A2 (de) 2003-07-23
PL361162A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
US6750236B2 (en) Propionic acid derivatives
NZ525119A (en) Propionic acid derivatives
US6506757B1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
KR100668026B1 (ko) 티아졸 및 옥사졸 유도체 및 그의 제약적 용도
AU2005304962B2 (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
KR100910440B1 (ko) 다이아실글리세롤 아실트랜스퍼레이즈 억제제
JP5043645B2 (ja) カルボン酸
WO2007008994A2 (en) Glutamate aggrecanase inhibitors
AU765203B2 (en) Sulfonamide derivatives having oxadiazole rings
AU7446600A (en) Novel diarylamide derivatives and use thereof as medicines
JPWO2002046176A1 (ja) ペルオキシソーム増殖剤応答性受容体の活性化剤
JPH11246527A (ja) Ｍｍｐ−８阻害剤
CA2463226A1 (en) Acetic acid derivatives
US20040024029A1 (en) Thiazole and oxazole derivatives
EP1726586A1 (de) Dihydronaphthalenderivate und Arzneimittel, die diese als Wirkstoff enthalten
KR20030059175A (ko) Ｐｐａｒ-알파 활성화 성질을 갖는 프로피온산 유도체
JP2005272419A (ja) ヒストン脱アセチル化酵素阻害剤
EP4008716A1 (de) Neue inhibitoren von insulinähnlichen wachstumsfaktor 2 mrna-bindenden proteinen
KR100621294B1 (ko) 옥사졸 유도체 및 이의 인슐린 증감제로서의 용도
JPWO2006028038A1 (ja) Ｍｍｐ−１３を選択的に阻害するスルホンアミド誘導体
WO2016077163A1 (en) Histone deacetylase inhibitors and uses thereof
ES2352071T3 (es) Derivados de tirosina sustituidos con n-fenilacroloilo como agonostas de hppar alfa y de hppar gama.
WO2008069611A1 (en) N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic diseases comprising same

Legal Events

Date Code Title Description
PSEA Patent sealed